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A B S T R A C T
Nicorandil is a hybrid angina therapeutic agent that has nitric oxide (NO) action and the ability to open ATP-
sensitive K+ channels (KATP channels). A transient increase in NO and intracellular Ca
2+ has been demonstrated
to be highly involved in the diﬀerentiation and activation of osteoclasts. The objective of this study was to verify
that the pharmacological eﬀect of nicorandil suppresses the diﬀerentiation process of osteoclasts in vitro.
Although little authentic NO production was detected in the culture medium in osteoclast formation assays,
NO production increased only in the presence of nicorandil. The number of osteoclasts decreased markedly at
late time-points after nicorandil addition compared with the number at early time-points. Both the number of
TRAP-positive multinucleated cells and the number of cells that obtained F-actin rings decreased in the
presence of nicorandil in a concentration-dependent manner. The osteo assay showed that the bone resorption
area was also reduced with nicorandil in a concentration-dependent manner. An inhibition recovery experiment
was conducted by adding a soluble guanylyl cyclase (sGC) inhibitor (ODQ) and a KATP channel-opening
inhibitor (glibenclamide) during the osteoclast formation process. In the inhibition recovery experiment, the
inhibitory eﬀect of nicorandil on osteoclastogenesis was blocked by the addition of ODQ and glibenclamide.
These results suggest that both the NO and KATP channel-opening activity of nicorandil inhibit osteoclast
diﬀerentiation. Further study of nicorandil may lead to the development of drugs for osteoporosis treatment.
1. Introduction
Nicorandil (N-[2-hydroxyethyl]-nicotinamide nitrate) is a hybrid
angina therapeutic agent, similar to the nitric acid drugs, which have
nitric oxide (NO) action and the ability to open ATP-sensitive K
channels (KATP channels) (Minamiyama et al., 2007). Its pharmacolo-
gical action involves the activation of guanylate cyclase (GC) by its NO
action, followed by increasing cyclic guanosine monophosphate
(cGMP) levels. As a consequence, cGMP-dependent protein kinase
(PKG) is activated. However, it has the ability to open KATP channels.
This activity increases K+ ﬂow out of the cell membrane, followed by
hyperpolarization and closing of Ca2+ channels. As a consequence, the
coronary artery relaxes due to the decreasing intracellular Ca2+
concentration (Horinaka, 2011; Holzmann et al., 1992).
Bone diseases, such as osteoporosis and periodontal disease, are
caused by increased bone resorption resulting from excessive osteoclast
activity. Thus, a therapeutic agent that can control the diﬀerentiation
process is required. Low NO concentrations inhibit osteoclast forma-
tion and activity during the osteoclast diﬀerentiation stage in murine
marrow cultures (Holliday et al., 1997). Furthermore, RANKL, which
promotes osteoclast formation, induces expression of nitric oxide
synthase (NOS) and NO production in osteoclasts through NF-κB-
and IFN-β-mediated mechanisms and regulates excessive cell activity
(Zheng et al., 2006). Gene disruption of the entire NOS system
enhances BMD and bone turnover in mice in vivo (Sabanai et al.,
2008). The endogenous NO / NOS system is important for maintaining
bone homeostasis. NO is believed to play a role of suppressing
excessive osteoclast formation and bone resorption by self-regulation
of osteoclast formation.
Ca2+ concentrations in osteoclasts increase upon increases in
extracellular ATP (Yu and Ferrier, 1993), which causes the activation
of a Ca2+-dependent K+ channel (Weidema et al., 1997). On the other
hand, KATP channels are inhibited by intracellular ATP concentration
increases, and the activation of these channels reduces intracellular
Ca2+ concentrations. Ca2+ functions as a ubiquitous second messenger
that can adjust diverse signalling pathways in the diﬀerentiation
process of osteoclasts (Berridge et al., 2003). Many diﬀerent stimuli,
such as extracellular acidiﬁcation and Ca2+ concentrations, have been
shown to regulate the Ca2+ concentration in osteoclasts (Xia and
Ferrier, 1995; Teti et al., 1989). Calcineurin is a phosphatase that
regulates the phosphorylation state of nuclear factor of activated T cell
c1 (NFATc1) and is known to be regulated by intracellular Ca2+.
Transcription by NFATc1 is greatly inﬂuenced by an increase in the
intracellular Ca2+ concentration (Kim and Kim, 2014; Zhou et al.,
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2011).
The objective of this study was to examine the inhibitory eﬀect of
nicorandil on the in vitro osteoclast diﬀerentiation process and its
mechanism.
2. Material and methods
2.1. Cells and materials
Mice were purchased from SHIMIZU Laboratory Supplies Co., Ltd.
(Kyoto, Japan). The experiment was conducted according to the
implementation guidelines of the Osaka Dental University animal
experiment protocol (approval number 15-02009). Human macro-
phage colony-stimulating factor (M-CSF) and soluble receptor activator
of NF-κB ligand (sRANKL) were purchased from Miltenyi Biotec
(Bergisch Gladbach, Germany). 1H-[1,2,4]oxadiazolo[4,3-a]quinoxa-
lin-1-one (ODQ) was purchased from Cayman Chemicals (Michigan,
USA), and glibenclamide was purchased from Tokyo Chemical Industry
Co., Ltd. (Tokyo, Japan). Nicorandil was a gift from Chugai
Pharmaceutical Co., Ltd. (Tokyo, Japan).
2.2. Osteoclast formation
According to the method described by Emori et al. (2015),
haematopoietic stem cells were collected from 5 to 8-week-old ddY
mice in which both ends of the femur and tibia were excised. All bone
marrow cells were collected by extrusion with a 27 G micro-injector
(Terumo, Tokyo, Japan). The collected cells were suspended in α-
minimal essential medium (α-MEM; Wako Pure Chemical Industries,
Ltd., Osaka, Japan) at pH 7.0, containing 10% foetal bovine serum
(FBS; SAFC Biosciences, Inc., Lenexa, KS), 1% GlutaMAX (Invitrogen
Corporation, Carlsbad, CA), and Penicillin-Streptomycin Mixed
Solution (Nacalai Tesque, Inc., Kyoto, Japan). They were passed
through Sephadex G-10 beads (GE Healthcare UK Ltd.,
Buckinghamshire, UK) packed in disposable Econo-Pac chromatogra-
phy columns (Bio-Rad, CA, USA). To remove the erythrocytes, the
centrifuged cell pellet was re-suspended in 0.83% NH4Cl-Tris-HCl
buﬀer solution (pH 7.4) and kept on the ice for 20 min. The sample was
centrifuged, and the pellet was re-suspended in α-MEM medium.
Approximately 5×104 cells were seeded into each well of a 96-well
plastic culture plate. Each well contained 25 ng/ml M-CSF and 100 ng/
ml sRANKL. Five diﬀerent concentrations of nicorandil (1 µm, 10 µm,
25 µm, 50 µm, and 100 µm) were added to the diﬀerent experimental
groups. Furthermore, two diﬀerent time-points of nicorandil addition
(25 µm, 0–3 days and 4–6 days) were planned. Both the control and
experimental groups were cultured at 37 °C in a 5% CO2/95% air
atmosphere for 6 days. The medium was changed every three days.
2.3. Rhodamine phalloidin and tartrate-resistant acid phosphatase
(TRAP) staining
After culture, the cells were ﬁxed in 4% paraformaldehyde. The
localization of F-actin was observed to conﬁrm diﬀerentiation to the
active form of osteoclasts. The ﬁxed cells were incubated with 0.1%
Triton X for 5 min. Then, the solution was replaced with rhodamine
phalloidin solution, and tissues were kept stationary in a dark room for
30 min, followed by F-actin staining. The ﬂuorescence signal was
detected by confocal laser scanning microscopy (LSM700, Carl Zeiss,
Oberkochen, Germany), and the number of osteoclasts with a ﬂuor-
escent ring was counted.
For TRAP staining, TRAP solution was added to the well and
incubated with the cells at 37 °C for 15 min. The number of cells with 3
or more nuclei was counted under an optical microscope.
2.4. NO production in the culture medium in osteoclast formation
assays
NO production was evaluated by measuring NO2
− and NO3
− in the
culture medium using the Griess method. Using the same procedures
and conditions as in the osteoclast formation experiment, cells were
incubated with 25 ng/ml M-CSF and 100 ng/ml sRANKL in the
presence or absence of 25 µm nicorandil. NO2
− and NO3
− in the
culture medium supernatants obtained at 0, 1, 3 and 6 days were
measured using NO2/NO3 Assay Kit-CII (Dojindo Co., Ltd.,
Kumamoto, Japan).
2.5. Osteo assay
Using the same procedures and conditions used in the osteoclast
formation experiment, cells were seeded into Osteo Assay Stripwell
Plates (Corning, MA, USA) coated with hydroxyapatite (1×8 wells). In
this study, the cells were cultured for 8 days, followed by ﬁxation with
1 M ammonium chloride. For von Kossa staining, 5% silver nitrate
solution was added, and the cells were kept stationary for 60 min under
light irradiation. Then, 5% sodium thiosulfate was added to develop the
black hydroxyapatite. The area of the bone resorption region was
quantiﬁed with an optical microscope. Quantiﬁcation was conducted
using Adobe Photoshop CC 2014 (Adobe System, CA, USA).
An osteo assay was also performed in the same manner for recovery
experiments that examined soluble guanylyl cyclase (sGC) inhibition by
ODQ and KATP channel inhibition by glibenclamide.
2.6. Recovery experiments examining sGC inhibition by ODQ and
KATP channel inhibition by glibenclamide
To verify the pharmacological mechanisms of osteoclast inhibition
by nicorandil, we performed an experiment in which sGC and KATP
channel opening were blocked by the addition of ODQ and glibencla-
mide during the osteoclast formation process (Marinko et al., 2015).
ODQ was dissolved in dimethyl sulfoxide (DMSO), and glibenclamide
was dissolved in N-N-dimethylformamide (DMF).
Cells were seeded onto 96-well plastic culture plates (5×104 cells/
well) with α-MEM medium (containing 10% FBS, 25 ng/ml M-CSF,
and 100 ng/ml sRANKL). Because the IC50 of nicorandil was 25 µm in
the osteoclast formation experiment, a concentration of 25 µm was
chosen. Four groups were investigated: 10 µm ODQ+25 µm nicorandil,
10 µm glibenclamide+25 µm nicorandil, 10 µm ODQ+10 µm gliben-
clamide+25 µm nicorandil, and 25 µm nicorandil alone (control
group). Furthermore, to verify the eﬀects of authentic NO production,
an experiment was performed by adding 10 µm ODQ in osteoclast
formation assay. Cells were cultured at 37 °C in a 5% CO2/95% air
atmosphere for 6 days. The medium was changed every three days.
2.7. Statistical analysis
The data are shown as the means ± standard error of mean.
Statistical signiﬁcance was deﬁned at a value of P < 0.05. Analysis of
statistically signiﬁcant diﬀerences between multiple groups was con-
ducted using one-way analysis of variance with the statistical software
SPSS, version 16 (IBM Japan, Tokyo, Japan) with a Bonferroni
correction.
3. Results
3.1. Nicorandil induces NO production in osteoclastogenesis
NO production increased in a time-dependent manner only in the
presence of nicorandil (Fig. 1A).
The number of osteoclasts with actin rings was 84.83 ± 4.57 in the
early time-point (0–3 days) nicorandil group and 59.33 ± 4.09 in the
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late time-point (4–6 days) nicorandil group. The number of osteoclasts
with actin rings decreased markedly in the late time-point group
compared with the number observed in the early time-point group
(Fig. 1B).
After TRAP staining, the number of osteoclasts was 90.67 ± 5.61 in
the early nicorandil time-point group and 59.88 ± 4.70 in the late
nicorandil time-point group. The number of multinuclear cells de-
creased markedly in the late time-point group (4–6 days) compared
with the number in the early time-point group (0–3 days) (Fig. 1C).
The number of osteoclasts was not increased by inhibiting sGC
using ODQ in the osteoclast formation assay (Fig. 1D and E).
Fig. 1. Nicorandil induces NO production in osteoclastogenesis. NO production increased in a time-dependent manner only in the presence of nicorandil (A). The number of osteoclasts
with actin rings decreased markedly in the late time-point group compared with the number observed in the early time-point group (B). After TRAP staining, the number of multinuclear
cells decreased markedly in the late time-point group (4–6 days) compared with the number in the early time-point group (0–3 days) (C). The number of osteoclasts was not increased by
inhibiting sGC using ODQ in the osteoclast formation assay (D and E). *P < 0.01 vs. control group.
F. Iwaki et al. European Journal of Pharmacology 793 (2016) 14–20
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3.2. Nicorandil inhibits osteoclast formation and diﬀerentiation
Observation of the ﬂuorescence signal after rhodamine phalloidin
staining revealed that active osteoclasts with F-actin rings no longer
increased in size, and the number of cells also decreased markedly with
nicorandil in a concentration-dependent manner (Fig. 2A–C). After
Fig. 2. Eﬀects of nicorandil on osteoclast formation and diﬀerentiation. A and D; control group (25 ng/ml M-CSF and 100 ng/ml sRANKL). B and E; nicorandil 10 µm group. C and F;
nicorandil 50 µm group. Observation of the ﬂuorescence signal after rhodamine phalloidin staining revealed that active osteoclasts with F-actin rings no longer increased in size, and the
number of cells also decreased markedly with nicorandil in a concentration-dependent manner (A–C and G). After TRAP staining, osteoclast formation was observed in the control
group. In the nicorandil groups, the size and number of osteoclasts decreased in a concentration-dependent manner (D–F and H). After von Kossa staining, the apatite resorption area
was signiﬁcantly decrease in a concentration-dependent manner (I). **P < 0.05 vs. control group, *P < 0.01 vs. control group.
F. Iwaki et al. European Journal of Pharmacology 793 (2016) 14–20
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TRAP staining, osteoclast formation was observed in the control group.
In the nicorandil groups, the size and number of osteoclasts decreased
in a concentration-dependent manner (Fig. 2D–F). The number of
osteoclasts with actin rings was 78.75 ± 8.79 in the control group and
37.13 ± 5.01 in the group treated with 1 µm nicorandil, half the
number of the control group. The number of osteoclasts with actin
rings was reduced gradually in a concentration-dependent manner
within the range of 10–100 µm (Fig. 2G). After TRAP staining, the
number of osteoclasts was 96.25 ± 6.57 in the control group, 51.75 ±
4.76 in the group treated with 10 µm of nicorandil and 39.08 ± 2.73 in
the group treated with 25 µm of nicorandil. The IC50 was between 10
and 25 µm (Fig. 2H). Although inhibition of diﬀerentiation of osteo-
clasts was statistically signiﬁcant, numerous undiﬀerentiated cells were
still present, and no signiﬁcant cytotoxicity was observed, even at a
concentration of 100 µm.
After von Kossa staining, the bone resorption rate was 93.40 ±
1.94% in the control group, indicating that the hydroxyapatite was
almost completely absorbed. However, the bone resorption rate was
56.36 ± 4.27% in the 10 µm nicorandil group and 35.3 ± 6.98% in the
50 µm nicorandil group. This decrease in the area of apatite resorption
was dose-dependent and statistically signiﬁcant (Fig. 2I).
3.3. Recovery experiments examining sGC inhibition by ODQ and
KATP channel inhibition by glibenclamide
To analyse the number of TRAP-positive cells as an index, the group
treated with 25 µm of nicorandil (approximately the IC50) was used as
the control group.　After both rhodamine phalloidin and TRAP stain-
ing, the more osteoclasts were present in the group treated with
glibenclamide and the group treated with ODQ. The diﬀerence was
even larger in the group treated by both agents (Fig. 3A–F).
The number of osteoclasts with actin rings was 21.33 ± 3.76 in the
control group and two-fold higher (37.67 ± 2.81) in the group treated
with 10 µm glibenclamide. The number was increased to 40.00 ± 4.97
in the group treated with 10 µm ODQ and signiﬁcantly increased in the
group treated with 10 µm glibenclamide+10 µm ODQ (72.67 ± 19.82)
(Fig. 3G). After TRAP staining, the number of osteoclasts was 18.50 ±
4.18 in the control group. The number was increased to 34.83 ± 5.72 in
the group treated with 10 µm glibenclamide and 37.83 ± 6.33 in the
group treated with 10 µm ODQ. In the group treated with 10 µm
glibenclamide and 10 µm ODQ, the number was signiﬁcantly increased
to 69.83 ± 18.29, which was equivalent to that of the group not treated
with nicorandil (Fig. 3H).
After von Kossa staining, the bone resorption rate was 50.26 ±
6.33% in the control group. The rate was 88.18 ± 3.87% in the 10 µm
glibenclamide group and 97.78 ± 0.34% in the 10 µm ODQ group. In
the 10 µm glibenclamide+10 µm ODQ group, the bone resorption rate
was 99.12 ± 0.37%, and the apatite resorption area was signiﬁcantly
increased (Fig. 3I).
4. Discussion
Nicorandil is a hybrid agent for angina therapy that has NO action
and the ability to open KATP channels. The pharmacological action of
NO in the myocardium is evident during the activation of cGMP-
dependent PKG via activation of GC and the resulting increase in cGMP
levels. NO synthesis involves NOS, and it has been implicated in blood
pressure adjustment and apoptosis as a cell signalling factor.
NOS proteins are classiﬁed as constitutive NOSs (cNOSs), which
always exist intracellularly at certain levels, and inducible NOSs
(iNOSs), which are induced by inﬂammation and stress. MacIntyre
et al. (1991) showed experimentally that NO inhibits the activity of
isolated rat osteoclasts and decreases the bone resorption area.
Thereafter, Kasten et al. (1994) showed enhanced bone resorption in
birds and mammals both in vitro and in vivo after inhibition of NOS, as
well as direct involvement of NO in osteoclast activity. Furthermore,
Zheng et al. (2006) demonstrated that RANKL induces iNOS expres-
sion and NO production in osteoclasts via NF-κB- and IFN-β-mediated
mechanisms and regulates excessive cellular activity. Endogenous NO
produced by iNOS has been reported to aﬀect bone remodelling during
fracture healing and in osteoarthritis (McCartney-Francis et al., 2001;
Diwan et al., 2000). Gene disruption of the entire NOS system
enhances BMD and bone turnover in mice in vivo (Sabanai et al.,
2008). According the above reports, NO is believed to play a role in
suppressing excessive osteoclast formation and bone resorption by self-
regulation of osteoclast formation.
NO is the primary activator of sGC and increases cGMP levels
(Derbyshire and Marletta, 2012). Various concentrations of NO
regulate osteoclast motility via cGMP-dependent protein kinase I and
vasodilator-stimulated phosphoprotein (Yaroslavskiy et al., 2005).
Homer et al. (2015) demonstrated that administration of sGC agonists
induces bone resorption, remodelling, and new bone formation in vivo.
In the present experiment, little authentic NO production was
detected in the culture medium in osteoclast formation assays.
Osteoclast inhibition by authentic NO production was not observed
in vitro. NO production was increased only in the presence of
nicorandil. The number of osteoclasts decreased markedly in the late
time-point nicorandil-addition group compared with the number in the
early time-point nicorandil-addition group. The number of osteoclasts
and the bone resorption area were increased by inhibiting sGC by
adding ODQ to 25 µm of nicorandil.
These results suggested that increased cGMP levels caused by the
activation of GC interacted with osteoclasts and sent a signal to inhibit
the diﬀerentiation of mononuclear osteoclasts into mature multinuc-
lear osteoclasts in accordance with increased NO concentrations.
The KATP channel was ﬁrst discovered in cardiomyocytes by Noma
(1983). Subsequent pharmacological studies revealed that the channel
exists not only in cardiomyocytes but also in pancreatic β cells, vascular
smooth muscle cells, and nerve cells (Ashcroft, 1988). When the KATP
of vascular smooth muscle cells is activated and the cell membrane is
depolarized, voltage-dependent Ca2+ channels are closed, the intracel-
lular Ca2+ concentration decreases, and the smooth muscle relaxes
(Quayle et al., 1997). Ca2+ concentrations in osteoclast increase with
increasing extracellular ATP (Yu and Ferrier, 1993), which leads to
activation of a Ca2+-dependent K+ channel (Weidema et al., 1997).
However, KATP channels are inhibited by increased intracellular ATP
concentrations, and the activation of these channels reduces intracel-
lular Ca2+ concentrations.
Intracellular Ca2+ kinetics are deeply involved in the diﬀerentiation
and activation of osteoclasts (Fu et al., 2015; Hwang and Putney, 2011;
Amano et al., 2000). In the diﬀerentiation process of osteoclasts,
RANKL produced by osteoblasts binds to RANK, and molecules such
as TNF receptor-associated factor 6 (TRAF6) assemble at the intracel-
lular domain of RANK. Then, kinases, such as extracellular signal
regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, are
activated. Finally, cell diﬀerentiation is proceeded by transcriptional
regulation via transcription factors, such as c-Fos, NFATc1, and PU.1
(Boyle et al., 2003; Teitelbaum, 2000). The expression level of the
NFATc1 gene is dramatically increased by RANK signalling during the
early stages of osteoclast diﬀerentiation. This activation requires the
activation of Ca2+-dependent signalling, and RANK signalling also
regulates the activation of this pathway (Takayanagi et al., 2002).
However, NFATc1-mediated transcription is not fully activated by only
a transient increase in Ca2+, but rather a sustained elevated level of
Ca2+ is required. To maintain the increase in intracellular Ca2+ levels,
Ca2+ inﬂux from outside the cell is required, and this mechanism is
referred to as store-operated Ca2+ entry (SOCE) (Parekh and Putney,
2005). SOCE promotes Ca2+ inﬂux from the extracellular space through
Ca2+ channels on the plasma membrane by sensing the depletion of
Ca2+ in the endoplasmic reticulum. This phenomenon, which is
dependent on the Ca2+ concentration in the endoplasmic reticulum,
is called capacitative Ca2+ entry (CCE) and is known to be the
F. Iwaki et al. European Journal of Pharmacology 793 (2016) 14–20
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Fig. 3. Study of the mechanism of nicorandil action using various inhibitors. A and D; 25 µm nicorandil +10 µm glibenclamide group, B and E; 25 µm nicorandil +10 µm ODQ group, C
and F; 25 µm nicorandil +10 µm glibenclamide +10 µm ODQ group. After both rhodamine phalloidin and TRAP staining, the more osteoclasts were present in the group treated with
glibenclamide and with ODQ. The diﬀerence was even larger in the group treated by both agents (A–F). The number of osteoclasts with actin rings was increased in the group treated
with 10 µm glibenclamide and with 10 µm ODQ. The number of osteoclasts with actin rings was signiﬁcantly increased in the group treated by both agents (G). After TRAP staining, the
number of osteoclasts was increased in the group treated with 10 µm glibenclamide and with 10 µm ODQ. The number of osteoclasts was signiﬁcantly increased in the group treated by
both agents (H). After von Kossa staining, the apatite resorption area was signiﬁcantly increase in the group treated with 10 µm glibenclamide and with 10 µm ODQ (I). Nico, nicorandil;
GLB, glibenclamide. **P < 0.05 vs. nicorandil 25 µm group, *P < 0.01 vs. nicorandil 25 µm group.
F. Iwaki et al. European Journal of Pharmacology 793 (2016) 14–20
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mechanism responsible for the sustained Ca2+ signal. In other cells of
the haematopoietic system, SOCE is known to play an important role in
the activation of NFAT signalling (Oh-Hora, 2009; Feske et al., 2003).
In this experiment, osteoclast formation was restored by addition of
glibenclamide, which inhibited the KATP channel-opening activity of
nicorandil. This ﬁnding demonstrated that KATP channel-opening
activity might result in the suppression of osteoclast diﬀerentiation.
This result suggested the following mechanism of nicorandil action. It
inhibits SOCE by depolarization, as seen in vascular smooth muscle. As
a consequence, the Ca2+ concentration in osteoclast precursor cells
decreases. Thus, cell diﬀerentiation by NFATc1 is inhibited.
In conclusion, our results suggested that through its NO action and
ability to open KATP channels, nicorandil inhibits the diﬀerentiation
and activity of osteoclasts in vitro. Further study of nicorandil might
lead to the development of osteoporosis treatment drugs.
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